Market Intelligence, Clinical Progress, and High-Purity Reagents for DNA Repair Pathway Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for XRCC5/Ku80 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | XRCC5 (Ku80) Recombinant Protein High purity (>95%), Endotoxin Controlled. Sequence Verified. Theoretical MW optimized for assay stability. |
View XRCC5 Products |
| Gene Delivery | XRCC5 Promise-ORF / Lentivirus Full-length ORF for stable cell line construction and overexpression validation. |
View XRCC5 Products |
| Benchmark Ab | Anti-XRCC5 Recombinant Antibody Recombinant positive control antibody for Western Blot, IHC, and IP validation. |
View XRCC5 Products |
| Validator | XRCC5 siRNA Set Target-specific siRNA pool for knockdown verification and functional specificity assays. |
View XRCC5 Products |
| Related Target A | XRCC6 (Ku70) Obligate heterodimerization partner of XRCC5. Crucial for reconstituting functional Ku70/Ku80 complex in vitro. |
View XRCC6 Products |
| Related Target B | PRKDC (DNA-PKcs) Serine/threonine-protein kinase recruited by the Ku70/Ku80 heterodimer to initiate NHEJ repair. |
View PRKDC Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Heterodimer Stability & Reconstitution | High-purity monomers with precise sequence verification to ensure stoichiometric reconstitution of the Ku70/Ku80 complex. |
| DNA-Binding Interference Screening | Endotoxin-controlled, highly purified proteins ensuring no nucleic acid contamination interferes with DNA-binding assays. |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) and sequence-verified positive controls included in the catalog. |
| False Positives in Knockdown | Validated multi-sequence siRNA pool included for robust target specificity checks. |
Live XRCC5/Ku80 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for XRCC5/Ku80 therapeutics is intensifying, with major players shifting focus from traditional cytotoxic combinations to targeted DNA Damage Response (DDR) synthetic lethality strategies. As first-generation DNA-PKcs inhibitors reach clinical evaluation, the next wave of R&D is targeting the upstream Ku70/Ku80 heterodimer to prevent NHEJ initiation altogether, particularly in homologous recombination (HR)-deficient cancers.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitors | Academic Spin-offs, Biotech Leaders | Ovarian Cancer, Triple-Negative Breast Cancer (TNBC) | In vitro DNA-binding inhibition assays (Requires ultra-pure XRCC5/XRCC6 proteins) |
| PROTAC / Degraders | Targeted Protein Degradation Pioneers | Hematological Malignancies, Refractory Solid Tumors | Ternary complex formation assays & stable cell line validation (Requires Lentivirus ORF) |
| Combination Biologics | Global Oncology Pharma | Radio-resistant Cancers | Synergy screening & target knockdown verification (Requires validated siRNA sets) |